Proteomic data derived from Immunovia’s IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases
LUND, SWEDEN – Immunovia AB, (“Immunovia”) a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced results from a study in their development pipeline, published in the peer-reviewed Journal of Proteome Research. These are the first proteomic data allowing a differential analysis of four different inflammatory rheumatic diseases (IRDs).Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms. The aim of the study was to achieve protein